Abstract
Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Current Enzyme Inhibition
Title:Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Volume: 12 Issue: 2
Author(s): Bijo Mathew, Githa E. Mathew, Jerad Suresh, Gülberk Ucar, Rani Sasidharan, Sockalingam Anbazhagan, Jobin K. Vilapurathu and Venkatesan Jayaprakash
Affiliation:
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Abstract: Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Export Options
About this article
Cite this article as:
Mathew Bijo, Mathew E. Githa, Suresh Jerad, Ucar Gülberk, Sasidharan Rani, Anbazhagan Sockalingam, Vilapurathu K. Jobin and Jayaprakash Venkatesan, Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders, Current Enzyme Inhibition 2016; 12 (2) . https://dx.doi.org/10.2174/1573408012666160402001715
DOI https://dx.doi.org/10.2174/1573408012666160402001715 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Translational Alzheimer’s Disease Research)
Current Alzheimer Research Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Current Neuropharmacology The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Exploration of Various Proteins for the Treatment of Alzheimer's Disease
Current Drug Metabolism Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy Preface
Current Drug Targets - CNS & Neurological Disorders Preface
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets